- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Vimta Labs reported Q3 FY26 revenue of INR 100.5 Cr (+10.2% YoY) and PAT of INR 17.6 Cr (+0.4% YoY). For 9M FY26, revenue stood at INR 304.3 Cr (+20.7% YoY) and PAT at INR 56.4 Cr (+16.4% YoY). Growth was driven by pharmaceutical and food testing, despite some lags/deferrals in clinical research and analytical services. Biologics CRD services are set for Q1 next fiscal commercialization. The company doubled EMI/EMC testing capacity. Management anticipates a stronger Q4 and remains aligned with the FY22-27 revenue target of INR 500 Cr for next year. EBITDA margins are expected to remain stable, bolstered by digital transformation efforts.